Trial Profile

Phase 1/2 Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talactoferrin alfa (Primary)
Indications Nosocomial infections
Focus Therapeutic Use
Sponsors Agennix

Most Recent Events

01 Jun 2016 Status changed from recruiting to completed, as per results published in the Journal of Pediatrics.
01 Jun 2016 Results of the substudy published in the Journal of Pediatrics.
31 May 2016 Primary endpoint of rate of hospital acquired infections, including bacteremia, pneumonia, urinary tract infection, meningitis, and NEC has been met, according to results published in the Journal of Pediatrics.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com